Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) has announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for Lucid-MS (Lucid-21-302), clearing the way for the company to initiate Phase 2 clinical development of this first-in-class candidate for multiple sclerosis (MS). This regulatory milestone positions Quantum BioPharma to advance a therapy that could fundamentally alter the treatment landscape for MS by addressing the underlying neurodegenerative processes rather than solely managing immune system activity.
The upcoming Phase 2 trial is designed as a randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of Lucid-MS in individuals with MS. The trial will utilize both clinical and radiological measures to assess the drug's impact. With the IND now in effect, Quantum BioPharma has begun trial start-up activities, including site selection, and aims to commence patient enrollment and drug administration as expeditiously as possible.
Lucid-MS is distinguished from existing MS therapies by its mechanism of action: it is designed to provide neuroprotection by inhibiting demyelination, the process by which the protective myelin sheath around nerve fibers is damaged. Current treatments primarily modulate the immune system to reduce inflammatory attacks, but they do not directly prevent or reverse myelin loss. Lucid-MS targets protein arginine deiminase 2 (PAD2), an enzyme implicated in myelin degradation. In preclinical models, the compound has demonstrated the ability to both prevent and reverse myelin breakdown, offering a potential disease-modifying approach that could alter the course of MS.
The FDA's clearance is based on promising preclinical data and a favorable safety profile observed in Phase 1 trials involving healthy participants. In those earlier studies, Lucid-MS was well tolerated, supporting the progression to later-stage testing. As of March 31, 2026, Quantum BioPharma reported holding more than $10 million in cash, digital assets, and liquid investments, which may help fund the upcoming trial.
This development is particularly significant given the unmet need in MS treatment. While current therapies can reduce relapse rates and slow disability progression, they are not curative and often come with significant side effects. A therapy that directly targets the neurodegenerative component of MS could offer new hope for patients. Moreover, the potential to reverse myelin damage, if confirmed in clinical trials, would represent a paradigm shift in the management of this chronic condition.
The approval also underscores the strategic focus of Quantum BioPharma on innovative neuroscience. The company is dedicated to building a portfolio of assets for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. Its wholly owned subsidiary, Lucid Psycheceuticals Inc., is leading the development of Lucid-MS. Beyond this lead compound, Quantum has also developed UNBUZZD, a product for alcohol misuse, and retains a 19.84% stake in Unbuzzd Wellness Inc., which markets the OTC version, along with royalty payments from its sales.
As Quantum BioPharma moves forward with the Phase 2 trial, the medical community will be watching closely. If Lucid-MS proves effective in patients, it could become a cornerstone therapy for MS, offering a new approach that goes beyond symptom management to potentially halt or even reverse the disease's progression. The company's ability to execute the trial efficiently will be crucial in determining how quickly this promising candidate can reach those in need.
